133 related articles for article (PubMed ID: 7644664)
1. Newer antifolates in cancer therapy.
Schultz RM
Prog Drug Res; 1995; 44():129-57. PubMed ID: 7644664
[No Abstract] [Full Text] [Related]
2. Inhibitors of thymidylate synthase and glycinamide ribonucleotide transformylase.
Jackson RC
Adv Exp Med Biol; 1994; 370():179-83. PubMed ID: 7660885
[No Abstract] [Full Text] [Related]
3. Inhibition of folate-dependent enzymes by 7-OH-methotrexate.
Sholar PW; Baram J; Seither R; Allegra CJ
Biochem Pharmacol; 1988 Sep; 37(18):3531-4. PubMed ID: 2458733
[No Abstract] [Full Text] [Related]
4. Biochemical and biological studies on 2-desamino-2-methylaminopterin, an antifolate the polyglutamates of which are more potent than the monoglutamate against three key enzymes of folate metabolism.
Rosowsky A; Galivan J; Beardsley GP; Bader H; O'Connor BM; Russello O; Moroson BA; DeYarman MT; Kerwar SS; Freisheim JH
Cancer Res; 1992 Apr; 52(8):2148-55. PubMed ID: 1313737
[TBL] [Abstract][Full Text] [Related]
5. Cytotoxicity of antifolate inhibitors of thymidylate and purine synthesis to WiDr colonic carcinoma cells.
Smith SG; Lehman NL; Moran RG
Cancer Res; 1993 Dec; 53(23):5697-706. PubMed ID: 8242626
[TBL] [Abstract][Full Text] [Related]
6. Multifactorial resistance to 5,10-dideazatetrahydrofolic acid in cell lines derived from human lymphoblastic leukemia CCRF-CEM.
Pizzorno G; Moroson BA; Cashmore AR; Russello O; Mayer JR; Galivan J; Bunni MA; Priest DG; Beardsley GP
Cancer Res; 1995 Feb; 55(3):566-73. PubMed ID: 7834626
[TBL] [Abstract][Full Text] [Related]
7. The synthesis and biological activity of a series of 2,4-diaminopyrido[2,3-d]pyrimidine based antifolates as antineoplastic and antiarthritic agents.
Gossett LS; Habeck LL; Shackelford KA; Mendelsohn LG; Gates SB; Worzalla JF; Self TD; Theobald KS; Andis SL; Schultz RM; Shih C
Bioorg Med Chem Lett; 1999 Jan; 9(1):75-8. PubMed ID: 9990460
[TBL] [Abstract][Full Text] [Related]
8. Conformationally restricted analogues designed for selective inhibition of GAR Tfase versus thymidylate synthase or dihydrofolate reductase.
Boger DL; Labroli MA; Marsilje TH; Jin Q; Hedrick MP; Baker SJ; Shim JH; Benkovic SJ
Bioorg Med Chem; 2000 May; 8(5):1075-86. PubMed ID: 10882019
[TBL] [Abstract][Full Text] [Related]
9. A novel class of monoglutamated antifolates exhibits tight-binding inhibition of human glycinamide ribonucleotide formyltransferase and potent activity against solid tumors.
Habeck LL; Leitner TA; Shackelford KA; Gossett LS; Schultz RM; Andis SL; Shih C; Grindey GB; Mendelsohn LG
Cancer Res; 1994 Feb; 54(4):1021-6. PubMed ID: 8313357
[TBL] [Abstract][Full Text] [Related]
10. Folate status and the safety profile of antifolates.
Calvert H
Semin Oncol; 2002 Apr; 29(2 Suppl 5):3-7. PubMed ID: 12023786
[TBL] [Abstract][Full Text] [Related]
11. Carrier- and receptor-mediated transport of folate antagonists targeting folate-dependent enzymes: correlates of molecular-structure and biological activity.
Westerhof GR; Schornagel JH; Kathmann I; Jackman AL; Rosowsky A; Forsch RA; Hynes JB; Boyle FT; Peters GJ; Pinedo HM
Mol Pharmacol; 1995 Sep; 48(3):459-71. PubMed ID: 7565626
[TBL] [Abstract][Full Text] [Related]
12. Biochemistry and pharmacology of glycinamide ribonucleotide formyltransferase inhibitors: LY309887 and lometrexol.
Mendelsohn LG; Shih C; Schultz RM; Worzalla JF
Invest New Drugs; 1996; 14(3):287-94. PubMed ID: 8958184
[TBL] [Abstract][Full Text] [Related]
13. Synergistic interactions among antifolates.
Kisliuk RL
Pharmacol Ther; 2000 Mar; 85(3):183-90. PubMed ID: 10739873
[TBL] [Abstract][Full Text] [Related]
14. Design and synthesis of inhibitors of folate-dependent enzymes as antitumor agents.
Taylor EC
Adv Exp Med Biol; 1993; 338():387-408. PubMed ID: 8304144
[No Abstract] [Full Text] [Related]
15. LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes.
Shih C; Chen VJ; Gossett LS; Gates SB; MacKellar WC; Habeck LL; Shackelford KA; Mendelsohn LG; Soose DJ; Patel VF; Andis SL; Bewley JR; Rayl EA; Moroson BA; Beardsley GP; Kohler W; Ratnam M; Schultz RM
Cancer Res; 1997 Mar; 57(6):1116-23. PubMed ID: 9067281
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and antifolate activity of 5-methyl-5,10-dideaza analogues of aminopterin and folic acid and an alternative synthesis of 5,10-dideazatetrahydrofolic acid, a potent inhibitor of glycinamide ribonucleotide formyltransferase.
Piper JR; McCaleb GS; Montgomery JA; Kisliuk RL; Gaumont Y; Thorndike J; Sirotnak FM
J Med Chem; 1988 Nov; 31(11):2164-9. PubMed ID: 3184124
[TBL] [Abstract][Full Text] [Related]
17. Cell cycle effects of antifolate antimetabolites: implications for cytotoxicity and cytostasis.
Tonkinson JL; Marder P; Andis SL; Schultz RM; Gossett LS; Shih C; Mendelsohn LG
Cancer Chemother Pharmacol; 1997; 39(6):521-31. PubMed ID: 9118464
[TBL] [Abstract][Full Text] [Related]
18. Multiple folate enzyme inhibition: mechanism of a novel pyrrolopyrimidine-based antifolate LY231514 (MTA).
Shih C; Habeck LL; Mendelsohn LG; Chen VJ; Schultz RM
Adv Enzyme Regul; 1998; 38():135-52. PubMed ID: 9762351
[TBL] [Abstract][Full Text] [Related]
19. Deaza analogs of folic acid as antitumor agents.
Kisliuk RL
Curr Pharm Des; 2003; 9(31):2615-25. PubMed ID: 14529545
[TBL] [Abstract][Full Text] [Related]
20. Antifolate drug interactions: enhancement of growth inhibition due to the antipurine 5,10-dideazatetrahydrofolic acid by the lipophilic dihydrofolate reductase inhibitors metoprine and trimetrexate.
Galivan J; Nimec Z; Rhee M; Boschelli D; Oronsky AL; Kerwar SS
Cancer Res; 1988 May; 48(9):2421-5. PubMed ID: 2965613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
